About BTG/SERB Specialty Pharmaceuticals
BTG Specialty Pharmaceuticals provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. We are dedicated to delivering quality medicines that make a real difference to patients and their families through the development, manufacture, and commercialization of pharmaceutical products. Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. We are actively researching new uses for our products and seek opportunities to license or acquire additional products that enable specialist physicians to serve their patients better.
SERB (Société d’Étude et de Recherche Biologique) is a specialty pharmaceuticals group created in the 50’s.Our mission has always been to bring lifesaving drugs that meet high unmet medical needs. The Emergency care franchise has been developed with selected antidotes portfolio answering essential medical needs. In the last decade, the group has extended its portfolio with acquisitions addressing niche indications, enlarging the Rare Diseases franchise. In addition, SERB has continuously expanded its international presence to ensure a global availability of their medicines. SERB has accelerated its strategic transformation with a strong acquisition/licensing track record initiated the past 10 years.